Collegium Pharmaceutical Hits Day High with 13.7% Surge in Stock Price

Collegium Pharmaceutical, Inc. has experienced significant activity today, with the stock surging 13.7% and reaching an intraday high of USD 41.81. This performance stands in stark contrast to the S&P 500, which only managed a modest gain of 0.37% on the same day. Over the past week, Collegium has shown a robust increase of 16.81%, while its one-month performance reflects a gain of 17.48%.
In terms of annual performance, Collegium has delivered a return of 21.66%, outpacing the S&P 500's 17.53%. Year-to-date, the stock has risen by an impressive 41.92%, compared to the S&P's 15.55%. However, despite these positive trends, the company faces challenges, including a weak EBIT to Interest ratio of 1.55, indicating difficulties in servicing its debt. Additionally, the company reported a decline in pre-tax profit of 29.39% in its latest quarterly results.

With a market capitalization of USD 1,222 million, Collegium operates within the pharmaceuticals and biotechnology sector, showcasing a P/E ratio of 15.00 and a return on equity of 23.11%.